Navigation Links
A treatment for lung cancer: similar to Vitamin A but with few side effects.

The most logical treatment for cancer is a drug or substance that stops or prevents tumour growth, with no side effects and obliterating// or stopping cancer to spread.

With the same thought in mind, Washington University School of Medicine researchers now report that a compound related to vitamin A is useful in this direction.

It has been found effective in preventing or slowing tumour growth in mice prone to lung cancer.

The nomenclature of the compound reveals that it is called bexarotene. It doesn't cause the severe skin irritations that have limited the use of other vitamin A derivatives in cancer therapies.

Ming You, M.D., Ph.D., director of the Chemoprevention Program at the Siteman Cancer Center states, "In the cancer prevention field, you look for drugs that can be given to healthy patients who have a higher risk of developing cancer. These patients wouldn't want to take a medication that makes them feel sick when they don't have cancer. So the drugs should be very well-tolerated and not cause harmful side effects."

In the current study, due to appear in an upcoming issue of Oncogene, Yian Wang, M.D., Ph.D., associate professor of surgery, You, professor of surgery, and colleagues demonstrate that lung-cancer-susceptible mice receiving non-toxic doses of bexarotene ended up with fewer and smaller benign and malignant tumors than mice that were not treated with bexarotene. The researchers saw a reduction of almost 50 percent in terms of total tumor burden in mice who were given bexarotene for 12 weeks after the animals had already developed benign tumors following injection of a lung carcinogen.

"Seeing this magnitude of response in such a strongly susceptible mouse suggests bexarotene is a potentially viable lung cancer prevention candidate," You says.

The majority of lung cancer patients are not diagnosed until their cancer has reached an advanced stage, and current treatment regimens do not substantially improve the outcome for most of these patients.

"Advanced or metastatic cancer is sort of a genius at adapting," You says. "By that point, the cancer cells that have survived have overcome so many obstacles and gained so many abilities that they are difficult to kill. They have a very unstable genome that can change quickly to resist the treatments we use.”

Therefore it is best that the cancer is diagnosed earlier and treatment done at the earliest.


'"/>




Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Feeding channel created by malaria parasite - a new target for malaria treatments
3. Now umbilical cord helps in stroke treatment.
4. Now AIDS treatment comes dirt-cheap
5. Breast cancer treatment to be determined by gene test
6. Hemopurifier may revolutionise AIDS treatment
7. New drug helps boost cancer treatment
8. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
9. Experimental treatment for Ebola Virus Shows promising results in mice
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. New dimension in the treatment of female sexual dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology: